Advances in the Management of Metastatic Breast Cancer: Options Beyond First-Line Chemotherapy

Ayoub, J-P.; Verma, S.; Verma, S.

doi:10.3747/co.19.1024

Cited by 15 publications

(12 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The benefit in overall survival also constitutes a relevant goal, but usually multiple chemotherapy lines and cross-over designs render difficult to value this outcome 10, even if more recent data from population-based studies and clinical trials show an improvement, with a median overall survival increasing from 18 to 24 months in the last years 11-13. In contrast to the adjuvant setting, where multi-agent chemotherapy regimens containing anthracyclines and/or taxanes are standard, the single-agent therapy approach is preferred in metastatic disease, unless rapid disease control is required in view of pending visceral crisis.…”

Section: Discussionmentioning

confidence: 99%

“…Data on single agent gemcitabine in anthracycline and taxane pre-treated patients suggest an overall response rate ranging from 12% to 30%, but with significant haematological toxicity 10, where more favourable results have been observed in combination with taxanes 22-24. Among vinca alkaloids, vinorelbine is widely employed in pretreated breast cancer, in anthracycline and taxane pretreated patients yielding response rates ranging from 10% to 35%, depending on the amount of the pre-treatment 25.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Eribulin Mesylate in Pretreated Breast Cancer Patients: A Multicenter Retrospective Observational Study

Gamucci¹,

Michelotti²,

Pizzuti³

et al. 2014

J. Cancer

View full text Add to dashboard Cite

Background: Eribulin was recently approved in patients progressing after being treated with anthracyclines and taxanes and after two or more chemotherapy lines for advanced disease.Objectives: This multicenter observational retrospective study was performed in order to evaluate activity and tolerability of eribulin in real-world patient population.Methods: 133 advanced breast cancer patients pretreated with ≥ 2 chemotherapy lines for metastatic disease were retrospectively enrolled in the observational trial in 11 italian cancer centres.Results: A median of 5 cycles of eribulin (range, 1-15) were administered. Twenty-eight partial responses were observed, for an overall response rate of 21.1% (95%CI,14.1-28.0). A stable disease was recorded in 57 patients (42.8%), and a clinical benefit (response or stable disease lasting ≥ six months) was observed in 51 patients (38.3%, 95%CI, 30.1-46.6). The subgroup analysis showed that a significant improvement in term of partial response and clinical benefit was achieved when eribulin was administered in HER-2 negative tumors (p=0.01 and p=0.004, respectively) and when it is given as third-line (p=0.09 and p=0.02, respectively). Toxicity was manageable; fatigue is the most common side effect observed, usually of low-grade, and clearly cumulative-dose related.Conclusions: In this retrospective, observational analysis eribulin confirmed its efficacy and manageable tolerability even in real-world population and in heavily pretreated patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Eribulin Mesylate in Pretreated Breast Cancer Patients: A Multicenter Retrospective Observational Study

Gamucci¹,

Michelotti²,

Pizzuti³

et al. 2014

J. Cancer

View full text Add to dashboard Cite

show abstract

“…[4] HER2-positive subtype is a particularly aggressive clinical phenotype shown by approximately 20-30% patients and characterized by amplification or overexpression of the HER2 gene; patients of this subset generally benefit from anti-HER2-targeted therapy. [5] Triple negative breast cancer (TNBC) is another aggressive phenotype with a poor prognosis, classified as basal and defined as disease negative for HER2 as well as for estrogen and progesterone. About one-third cases have a central nervous system (CNS) metastasis.…”

Section: Introductionmentioning

confidence: 99%

Eribulin mesylate: A new therapeutic option for metastatic breast cancer

Aditya

2013

J Basic Clin Reprod Sci

View full text Add to dashboard Cite

More than a million women are diagnosed with breast cancer annually worldwide. Death from breast cancer is usually a result of chemotherapy-resistant metastatic disease. Eribulin mesylate is a recent addition to the therapeutic armamentarium for treating locally advanced or metastatic breast cancer (MBC) in patients who have received at least two prior chemotherapy regimens for late-stage disease. This synthetic analog, derived from a marine sponge macrolide halichondrin B, inhibits microtubule stability by blocking microtubule growth without affecting microtubule shortening. The US Food and Drug Administration has approved eribulin mesylate as a third-line treatment for MBC refractory to anthracyclines and taxanes based on a Phase III clinical trial showing significantly increased overall survival compared to treatment of investigator's. Asthenia, fatigue, neutropenia, alopecia, nausea, anorexia, and neuropathy are the most frequent adverse effects associated with this drug. The aim of this review was to highlight the importance of this drug in the management of breast cancer. Medline, Excerpta Medica database, cochrane database, medscape, Elsevier Scopus, and clinicaltrials.gov were searched using terms "eribulin," "E7389," "halichondrin," "metastatic breast cancer." Journal articles published from 2007 to 2012 discussing pharmacology and/or clinical trials were screened. The development of this microtubule inhibitor helps to address the need for additional effective regimens for patients progressing after standard treatment with anthracycline-and taxane-containing regimens.

show abstract

“…Although systemic treatment options for abc were previously reviewed in this journal 57 , an update for her2-negative abc that addresses additional considerations follows.…”

Section: Chemotherapy Optionsmentioning

confidence: 99%

Systemic Treatment Approaches in her2-Negative Advanced Breast Cancer—Guidance on the Guidelines

et al. 2015

View full text Add to dashboard Cite

Despite advancements in the treatment of early-stage breast cancer, many patients still develop disease recurrence; others present with de novo metastatic disease. For most patients with advanced breast cancer, the primary treatment intent is noncurative—that is, palliative—in nature. The goals of treatment should therefore focus on maximizing symptom control and extending survival. Treatments should be evaluated on an individualized basis in terms of evidence, but also with full respect for the wishes of the patient in terms of acceptable toxicity. Given the availability of extensive reviews on the roles of endocrine therapy and her2 (human epidermal growth factor receptor 2)–targeted therapies for advanced disease, we focus here mainly on treatment guidelines for the non-endocrine management of her2-negative advanced breast cancer in a Canadian health care context.

show abstract

Advances in the Management of Metastatic Breast Cancer: Options Beyond First-Line Chemotherapy

Cited by 15 publications

References 81 publications

Eribulin Mesylate in Pretreated Breast Cancer Patients: A Multicenter Retrospective Observational Study

Eribulin Mesylate in Pretreated Breast Cancer Patients: A Multicenter Retrospective Observational Study

Eribulin mesylate: A new therapeutic option for metastatic breast cancer

Systemic Treatment Approaches in her2-Negative Advanced Breast Cancer—Guidance on the Guidelines

Contact Info

Product

Resources

About